Optieum Biotechnologies partners with Precision BioSearch to appoint CSO

Precision BioSearch was delighted to partner with Optieum Biotechnologies Inc. (“Optieum”), a biotechnology company focused on discovering and developing innovative CAR-T cell therapies, to secure the appointment of Dr. Dan MacLeod as Chief Scientific Officer.

Dr. MacLeod is an experienced biotechnology leader and innovator in the cell therapy space with 20 years of experience in immunology, oncology, cancer immunotherapy, gene-editing and virology. Throughout his career, Dan has successfully led numerous teams in translating platform technologies into clinical candidate cell therapies, including four CAR-T therapies that advanced from early-stage research through IND-enabling studies and into Phase 1/2 clinical trials. Prior to joining the Optieum team, Dan was Senior Vice President of Discovery at ImmunoScape, where he led R&D for autologous TCR-T cell therapies. He also held roles of increasing responsibility during his time at Precision BioSciences, leading the discovery and development of gene-edited, allogeneic CAR-T cell therapies. Earlier in his career, Dan held roles at GlaxoSmithKline and the International AIDS Vaccine Initiative (IAVI).

“With its groundbreaking Eumbody System, Optieum is set to unlock the full therapeutic potential of CAR-T therapies. I’m thrilled to join this mission to bring transformative treatments to patients facing the most challenging diseases,” said Dr. MacLeod.

Welcoming Dan to the company, Shun Nishioka, CEO of Optieum said: 

We are thrilled to welcome Dan to Optieum’s executive leadership team. His deep expertise in cell and gene therapy product research, development and delivery will be instrumental in advancing our products into clinical trials.